Heat-Tolerant Covid-19 Vaccine by IISc

Source: TH

Why in News?

A heat-tolerant vaccine developed by the **Indian Institute of Science (IISc)** researchers is **said to be** effective against all **current strains of** <u>SARS-CoV-2</u> besides having the potential to be quickly adapted for future variants as well.



What are the Key Points Related to the Vaccine Developed by IISc?

- Background: According to IISc, while current vaccines are proven to be effective against most SARS-CoV-2 strains, their efficacy has declined due to rapid mutation by the virus.
- Antigen Selection: After analyzing various proteins found in the virus, the researchers selected two parts of SARS-CoV-2's spike protein, the S2 subunit and the <u>Receptor Binding Domain (RBD)</u> for designing their vaccine candidate.
 - The **S2 subunit is highly conserved.** It mutates much less than the S1 subunit, which is the target of most current vaccines and the RBD can provoke a robust immune response.
 - $\circ\,$ A hybrid protein, RS2, was created by combining the selected components.
 - The researchers then tested the effects of the protein in both mice and hamster models. They found that the hybrid protein triggered a strong immune response.

Note

A receptor-binding domain is a key part of a virus located on its 'spike' domain that allows it to dock to body receptors to gain entry into cells and lead to infection.

 The spike (S) protein of SARS-CoV-2, which plays a key role in the receptor recognition and cell membrane fusion process, is composed of two subunits, S1 and S2.



- Characteristics of RS2 Antigen:
 - Adaptability to Variants: The RS2 antigen can be customized to incorporate the RBD region of any new SARS-CoV-2 variant including XBB.1.5 and <u>IN.1 variants</u>.
 - This adaptability addresses concerns related to the virus's rapid mutation.
 - **Storage and Distribution:** RS2 antigen can be stored at room temperature for a month without requiring cold storage.
 - Economic Advantage: Reduced production and distribution costs make it economically viable.



UPSC Civil Services Examination, Previous Year Questions (PYQs)

Q. In the context of vaccines manufactured to prevent COVID-19 pandemic, consider the following statements: (2022)

- 1. The Serum Institute of India produced COVID-19 vaccine named Covishield using mRNA platform.
- 2. Sputnik V vaccine is manufactured using vector-based platform.
- 3. COVAXIN is an inactivated pathogen-based vaccine.

Which of the statements given above are correct?

(a) 1 and 2 only
(b) 2 and 3 only
(c) 1 and 3 only
(d) 1, 2 and 3

Ans: (b)

PDF Refernece URL: https://www.drishtiias.com/printpdf/heat-tolerant-covid-19-vaccine-by-iisc